Abstract
Cellular immunotherapy such as that initiated by dendritic cell (DC) is capable of eradicating cancer stem cells and restoring the homeostasis imbalance, and therefore has emerged as a promising approach to cure tumor. The first therapeutic DC vaccine in world has been approved by American FDA. However, the satisfactory therapeutic benefits of DC vaccine observed in vitro and in vivo (animal) studies could barely be recapitulated in clinical settings. The advantages of DC immunotherapy, achievements and challenges are introduced.
| Original language | English |
|---|---|
| Pages (from-to) | 398-400 |
| Number of pages | 3 |
| Journal | Journal of Leukemia and Lymphoma |
| Volume | 22 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2013 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Dendritic cell
- Immunotherapy
- Neoplasms
- Neoplastic stem cells
Fingerprint
Dive into the research topics of 'Dendritic cell immunotherapy: Stumble and expects'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver